Dexcom G7 Class Action Lawsuit: Full 2026 Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

The Dexcom G7 class action lawsuit is gaining serious momentum heading into 2026, with thousands of users reporting sensor failures, dangerously inaccurate glucose readings, and adhesive defects that put diabetic patients at real medical risk. If you wore a Dexcom G7 sensor and experienced problems, you might be entitled to compensation.

This guide covers everything you need to know about the litigation right now. You’ll find the latest case updates, who qualifies, estimated payout amounts, filing deadlines, and step-by-step instructions for getting involved.

One number stands out: the FDA’s MAUDE database has logged over 14,000 adverse event reports tied to Dexcom CGM devices in recent years. That’s not a small blip. That’s a pattern.

See also: Lebanon CT Budget Shortfall Lawsuit 2026: What You Need

Here’s what matters most for people affected by this device in 2026.

What Is the Dexcom G7 Class Action Lawsuit

The Dexcom G7 class action lawsuit is a legal action brought by users of the Dexcom G7 continuous glucose monitor who suffered harm from device malfunctions. These claims center on sensor failures, inaccurate blood sugar readings, and adhesive defects that caused real medical consequences for diabetic patients.

Dexcom Inc., headquartered in San Diego, California, manufactures the G7 as its flagship CGM system. The company markets it as the most accurate and reliable wearable glucose monitor available. Plaintiffs disagree with that claim.

The lawsuits allege that Dexcom knew about recurring product defects but failed to warn consumers or issue timely fixes. Some claims fall under product liability law. Others target Dexcom for breach of warranty and negligent manufacturing.

What makes this different from a typical product complaint is the severity. Inaccurate glucose readings can lead to incorrect insulin doses. That can trigger hypoglycemia (dangerously low blood sugar) or hyperglycemia (dangerously high blood sugar). Both conditions can cause seizures, coma, or death.

Think of it this way: if your car’s speedometer showed 30 mph while you were actually going 80, you’d call that a safety defect. A faulty glucose monitor is the medical equivalent, except the stakes involve your life.

Dexcom G7 Lawsuit 2026: Where Things Stand

As of early 2026, the Dexcom G7 lawsuit is in active litigation with cases filed across multiple federal districts. Attorneys representing plaintiffs have pushed for consolidation under multidistrict litigation (MDL) to streamline the growing number of claims.

Several law firms began investigating Dexcom G7 complaints in late 2024 and early 2025. By mid-2025, formal lawsuits were filed in federal courts. The number of individual plaintiffs has continued to grow throughout late 2025 and into 2026.

The judicial panel on multidistrict litigation has been evaluating whether to assign all Dexcom G7 cases to a single federal judge. MDL consolidation would speed up the pretrial process and avoid conflicting rulings across different courts.

No class has been formally certified yet in 2026. That doesn’t mean the case is weak. Class certification is a lengthy process, and most major product liability cases take 18 to 36 months to reach that stage.

• Multiple federal lawsuits are active as of 2026
• MDL consolidation is under consideration
• Class certification has not yet been granted
• Plaintiff numbers continue to grow each quarter

The legal landscape for Dexcom G7 claims in 2026 is still developing, but the trajectory points toward a significant multi-plaintiff action by late 2026 or early 2027.

Latest Dexcom G7 Lawsuit Update for 2026

The most recent Dexcom G7 lawsuit update shows that plaintiff attorneys filed new motions in early 2026 seeking document discovery from Dexcom Inc. This discovery phase is critical because it forces Dexcom to hand over internal records about product testing, quality control, and complaint handling.

Discovery is where class action cases get interesting. It’s when internal emails, engineering reports, and executive memos come to light. If Dexcom’s own documents show the company knew about sensor defects before they hit the market, that strengthens every plaintiff’s case significantly.

Key 2026 developments include:

• New plaintiff filings in Q1 2026 from users in Texas, Florida, and California
• Discovery motions seeking Dexcom’s internal testing and quality control data
• Growing coordination among plaintiff law firms for potential MDL transfer
• Ongoing FDA review of additional adverse event reports filed in 2025 and 2026

No bellwether trials have been scheduled yet. Bellwether trials are test cases that help both sides gauge how juries might respond. These typically get scheduled 12 to 18 months after MDL consolidation.

Stay alert for updates in the second half of 2026. That’s when the case’s direction will become much clearer.

Key Takeaway: The Dexcom G7 lawsuit is actively progressing through federal courts in 2026, with MDL consolidation and document discovery as the two biggest milestones to watch.

Dexcom Class Action Lawsuit Settlement Prospects

A Dexcom class action lawsuit settlement has not been reached as of 2026. The case is still in its early-to-mid litigation stages, which means no settlement offer is currently on the table.

That said, product liability cases against medical device companies have a strong track record of settling before trial. Most defendants prefer to settle rather than risk a massive jury verdict, especially when the evidence includes FDA adverse event data and internal company documents.

Settlement negotiations usually begin after the discovery phase wraps up. In the Dexcom G7 case, that likely means meaningful settlement talks won’t start until late 2026 at the earliest, with a more realistic window of 2027.

Several factors will influence whether Dexcom settles and for how much:

• Volume of plaintiffs: More claimants means more pressure on Dexcom
• Severity of injuries: Hospitalizations and emergency events carry higher value
• Internal documents: If discovery reveals Dexcom knew about defects, settlement becomes more likely
• FDA actions: Any formal recall or enforcement action strengthens the plaintiffs’ position

For comparison, other medical device class action settlements in the CGM and insulin pump space have ranged from $10 million to $500 million in total settlement funds, depending on the number of affected users and the severity of harm.

Dexcom reported $3.6 billion in revenue for 2024. The company has the financial capacity to fund a significant settlement if the evidence warrants it.

Dexcom Lawsuit Payout Amounts: What to Expect

Individual payout amounts from a Dexcom lawsuit will likely range from $500 to $50,000 or more depending on the severity of harm each claimant suffered. Minor claims involving sensor inconvenience will pay less. Claims involving hospitalization or serious medical events will pay substantially more.

No official payout schedule exists yet since there is no settlement. These estimates come from analyzing comparable medical device lawsuits and the range of injuries reported by Dexcom G7 users.

These figures are projections based on similar litigation outcomes. Actual payouts will depend on the total settlement fund size, the number of approved claims, and how the court structures the payout tiers.

People with strong medical records showing a direct link between a G7 malfunction and their health crisis will receive the highest payouts. Documentation is everything in these cases.

Think of it like insurance claims after a car accident. A fender bender pays less than a totaled car with injuries. The same logic applies here.

Who Qualifies for the Dexcom Lawsuit

You may qualify for the Dexcom lawsuit if you used a Dexcom G7 continuous glucose monitor and experienced a device malfunction that caused you harm. The key element is that the device failure must have led to some form of injury, medical event, or financial loss.

You likely qualify if you meet these conditions:

• You purchased or were prescribed a Dexcom G7 CGM
• The sensor gave inaccurate glucose readings
• The sensor fell off prematurely due to adhesive failure
• The sensor stopped working during its intended wear period
• You experienced a medical event (hypoglycemia, hyperglycemia, ER visit) because of the malfunction
• You suffered financial loss from buying replacement sensors out of pocket

You don’t need to have been hospitalized to qualify. Even consistent sensor failures that forced you to buy replacements or switch devices may make you eligible for a claim.

Both Type 1 and Type 2 diabetes patients who used the G7 are eligible. Caregivers of minor children who wore the G7 can file on behalf of their child.

Geographic location matters too. Most of the active cases are in U.S. federal courts. You need to be a U.S. resident or have purchased the device in the United States.

Key Takeaway: If your Dexcom G7 malfunctioned and caused you medical harm or financial loss, you likely qualify to join the lawsuit, and you don’t need to have been hospitalized.

Dexcom Lawsuit Eligibility Requirements Explained

Eligibility requirements for the Dexcom lawsuit boil down to three things: you used the product, the product failed, and the failure caused you harm. Attorneys evaluating claims look at these factors during their intake process.

Here is a straightforward breakdown of what you need:

Strong claims will have medical records showing treatment for a glucose-related event that coincided with a documented G7 sensor failure. Your Dexcom app logs can serve as evidence since they record sensor readings, error alerts, and sensor session data.

Weaker claims might lack documentation but still qualify if the claimant can provide a detailed account of the malfunction and any resulting harm. Attorneys can sometimes obtain records from Dexcom’s own customer complaint database.

If you reported your sensor problem directly to Dexcom’s customer support, that’s helpful. Those complaints are logged internally and can be subpoenaed during discovery.

Keep every receipt, screenshot, and medical record related to your Dexcom G7 experience. Even old ones. They could be worth real money.

How to File a Dexcom G7 Lawsuit

Filing a Dexcom G7 lawsuit in 2026 starts with contacting a plaintiff’s attorney who handles medical device or product liability cases. You don’t pay anything upfront. These cases operate on a contingency fee basis, meaning the attorney only gets paid if you win or settle.

Step-by-step filing process:

1. Gather your evidence: Collect medical records, Dexcom app screenshots, purchase receipts, insurance claims, and any photos of sensor failures
2. Contact an attorney: Reach out to a law firm handling Dexcom G7 claims. Many offer free case evaluations
3. Complete a case review: The attorney’s team will assess your situation, timeline, and evidence
4. Sign a retainer agreement: If your case qualifies, you’ll sign an agreement that outlines the attorney’s contingency fee
5. Join the litigation: Your attorney files your claim either individually or as part of the consolidated class action or MDL

The entire intake process usually takes 1 to 3 weeks. After that, your attorney handles most of the legal work while you wait for case developments.

You don’t need to go to court in person for the early stages. Most communication happens by phone, email, or secure online portals. If the case reaches trial or requires a deposition, your attorney will prepare you well in advance.

Filing sooner rather than later is smart. Statutes of limitation set hard deadlines, and evidence gets harder to obtain as time passes.

Key Takeaway: Filing a Dexcom G7 lawsuit costs nothing upfront, takes about 1 to 3 weeks to get started, and your attorney handles the heavy lifting from there.

Dexcom G7 Sensor Failure Lawsuit Claims

Sensor failure is the single most common complaint driving the Dexcom G7 lawsuit. Plaintiffs report that G7 sensors stop working mid-session, provide no data for hours, or display error messages that render the device useless during critical monitoring periods.

Each G7 sensor is designed to last 10 days. Many users report failures within the first 24 to 48 hours. When a sensor fails early, diabetic patients lose their continuous glucose monitoring and must rely on painful finger-prick tests or go without data entirely.

Common sensor failure modes reported:

• Sensor stops transmitting data to the paired smartphone
• “Sensor error” message appears and never resolves
• Sensor readings flatline at an incorrect number
• Sensor warm-up period extends far beyond the normal 30 minutes
• Bluetooth connectivity drops repeatedly

These aren’t minor annoyances. For a Type 1 diabetic, losing CGM data during sleep can mean missing a dangerous low blood sugar event. That can lead to a seizure or worse before the person even wakes up.

Plaintiffs argue that Dexcom’s quality control process failed to catch these defects before shipping sensors to consumers. The lawsuits claim this constitutes negligent manufacturing.

Dexcom G7 Inaccurate Readings Lawsuit

Inaccurate glucose readings from the Dexcom G7 represent the most dangerous defect alleged in the lawsuit. When a CGM tells a diabetic patient their blood sugar is normal but it’s actually dangerously low, the consequences can be life-threatening.

The G7 is marketed with a MARD (Mean Absolute Relative Difference) of 8.2%, which Dexcom promotes as industry-leading accuracy. Plaintiffs claim real-world performance frequently falls far short of that benchmark.

Types of inaccuracy reported:

• Readings showing normal glucose when the patient was actually hypoglycemic
• Readings showing high glucose, prompting unnecessary insulin doses that caused dangerous lows
• Readings lagging 30 to 60 minutes behind actual blood sugar levels
• Sudden jumps of 100+ mg/dL in readings within minutes, which is physiologically impossible

The insulin dosing problem is especially serious. The Dexcom G7 is FDA-approved for making treatment decisions. That means patients are supposed to trust the number on their screen to decide how much insulin to take.

If the number is wrong and a patient takes too much insulin, they can enter severe hypoglycemia within minutes. That can cause loss of consciousness, seizures, brain damage, or death.

Several plaintiffs have reported emergency room visits directly caused by taking insulin based on a false high reading from their G7 sensor.

This is not a situation where the device is “close enough.” When your life depends on a number being right, close enough is not acceptable.

Dexcom G7 Problems Reported by Users

Users have reported a wide range of Dexcom G7 problems beyond just sensor failures and inaccurate readings. The FDA’s MAUDE (Manufacturer and User Facility Device Experience) database contains thousands of adverse event reports for Dexcom devices, with G7-specific complaints rising sharply since the device’s U.S. launch.

Most frequently reported problems include:

• Sensor falling off within 1 to 3 days
• Painful insertion site reactions, including bleeding and bruising
• Severe skin irritation and allergic contact dermatitis from adhesive
• App crashes and lost data during critical monitoring windows
• Transmitter communication failures
• Customer service delays when requesting replacements

Online diabetes forums and social media groups have amplified these complaints. Many users describe a pattern: they contact Dexcom support, receive a replacement sensor, and the replacement fails too. This cycle repeats until patients lose confidence in the device entirely.

What strikes many patients is that Dexcom charges a premium price for the G7. Insurance copays and out-of-pocket costs are significant. Paying top dollar for a device that fails repeatedly feels like a betrayal of trust.

Key Takeaway: Dexcom G7 users have reported a consistent pattern of sensor failures, adhesive problems, inaccurate readings, and poor customer service responses, all of which fuel the growing lawsuit.

Dexcom G7 FDA Recall History

The FDA has issued safety communications and recalls related to Dexcom products, although the full recall history specifically for the G7 model requires careful distinction from the older G6 system. Both devices have been subject to regulatory scrutiny.

In November 2023, Dexcom issued a voluntary recall (classified as Class I, the most serious type) for certain Dexcom G6 sensors due to potential over-reporting of glucose levels. While this technically applied to the G6, it raised questions about quality control across Dexcom’s manufacturing processes.

The G7 has been the subject of multiple FDA adverse event reports and safety alerts. The FDA’s MAUDE database shows a significant uptick in G7-related complaints throughout 2024 and 2025.

Key FDA actions related to Dexcom:

• Class I recall of Dexcom G6 sensors (November 2023) for potential inaccurate high readings
• Thousands of MAUDE reports for G7 sensor malfunctions filed between 2023 and 2025
• Ongoing FDA monitoring of G7 performance post-market
• FDA post-market surveillance requirements for Dexcom’s CGM product line

A Class I recall for the G7 specifically has not been issued as of early 2026. But plaintiffs argue that the volume of adverse event reports justifies a recall or at minimum a strengthened warning label.

The FDA recall history matters for the lawsuit because it establishes a regulatory paper trail. If the FDA found problems serious enough to issue recalls for the G6, it bolsters claims that Dexcom has systemic quality issues.

Dexcom G7 Adhesive Problems Lawsuit

Adhesive failure is a major component of the Dexcom G7 lawsuit, with users reporting that sensors detach from the skin well before their 10-day intended wear period. For a device that costs real money and that patients depend on for continuous monitoring, a sensor that falls off after two days is a serious defect.

Common adhesive complaints:

• Sensor peels at the edges within 24 to 48 hours
• Complete detachment during normal activity (showering, sleeping, light exercise)
• Adhesive residue that causes skin irritation after removal
• Allergic contact dermatitis from adhesive chemicals, including isobornyl acrylate (IBOA)

The IBOA issue is particularly significant. Isobornyl acrylate is a chemical used in medical device adhesives that is a known skin sensitizer. Some patients develop severe allergic reactions, including redness, blistering, and permanent scarring at the sensor site.

Patients have tried everything to keep sensors attached: overtape patches, skin adhesive sprays, and barrier wipes. The fact that an entire cottage industry of aftermarket sensor adhesive solutions exists tells you something about the scope of this problem.

Plaintiffs argue that Dexcom should have reformulated its adhesive or at minimum warned users about the allergy risk from IBOA. The company’s failure to do either forms the basis of the adhesive-related claims.

Dexcom G7 Health Risks Linked to Defects

The health risks from Dexcom G7 defects go beyond inconvenience. Real people have ended up in emergency rooms, intensive care units, and worse because a device they trusted with their life gave them bad information.

Primary health risks include:

• Severe hypoglycemia: When a false high reading causes a patient to take excess insulin, blood sugar can crash to dangerous levels within minutes. Symptoms include confusion, seizures, loss of consciousness, and death
• Diabetic ketoacidosis (DKA): When a false low reading causes a patient to skip insulin, blood sugar can spike uncontrollably. DKA can lead to coma and death if untreated
• Skin infections: Open wounds from adhesive reactions can become infected, especially in diabetic patients whose wound healing is already compromised
• Psychological harm: Chronic device failures create anxiety, sleep disruption, and loss of confidence in diabetes management

The hypoglycemia risk is the most urgent. A person with Type 1 diabetes who relies on their G7 for overnight monitoring could enter severe hypoglycemia during sleep. Without an accurate alarm from the CGM, they may not wake up.

This scenario, sometimes called “dead in bed syndrome” in the diabetes community, is every diabetic patient’s worst fear.

These health risks are exactly why the Dexcom G7 lawsuit carries weight. This is not about a gadget that doesn’t work perfectly. It’s about a medical device that can kill you when it fails.

Key Takeaway: Dexcom G7 defects can cause severe hypoglycemia, diabetic ketoacidosis, skin infections, and serious psychological harm, making this far more than a consumer inconvenience case.

Dexcom G7 Lawsuit Deadline in 2026

The deadline to file a Dexcom G7 lawsuit depends on your state’s statute of limitations for product liability and personal injury claims. Most states set this deadline at 2 to 4 years from the date of injury or the date you discovered (or should have discovered) the connection between your injury and the device.

There is no single universal deadline for every claimant. Your filing window depends on where you live and when your injury occurred.

If your G7 malfunction and resulting injury happened in 2024, your deadline in many states could arrive as early as 2026. That means waiting is risky.

The discovery rule can extend some deadlines. If you didn’t realize your medical event was caused by a sensor defect until later, the clock might start from the date of discovery rather than the date of injury. This varies by jurisdiction.

Bottom line: if you think you have a claim, talk to an attorney now. Waiting until the last minute creates unnecessary risk, and late filings are typically dismissed with no second chances.

On a related note, check out Frivolous Lawsuit Examples: Real Cases and Costs in 2026

Dexcom G7 vs G6 Lawsuit Differences

The Dexcom G7 and G6 lawsuits share common themes, but there are meaningful differences in the allegations, device technology, and regulatory history. Understanding these differences matters if you’re trying to figure out which case applies to your experience.

The G6 recall in November 2023 specifically addressed sensors that could over-report glucose levels. This is a known, documented, FDA-confirmed defect. Plaintiffs in G6 cases have this recall as strong evidence.

G7 cases don’t have a formal recall to point to yet. But the G7’s integrated transmitter design introduces new failure points. When the sensor and transmitter are built into one unit, a failure in either component kills the entire device.

Explore this too: NFL Lawsuit Kelly and Sons 2026: Settlement and Payouts

Some plaintiffs have claims involving both devices, especially patients who switched from the G6 to the G7 and experienced problems with each. Attorneys can file claims covering both product generations.

The G7 cases may ultimately prove stronger in some respects. The device is newer, the complaint volume is growing faster, and the integrated design means there are fewer excuses for Dexcom to blame user error.

Dexcom Lawsuit Attorney Fees and Costs

Attorney fees for the Dexcom G7 lawsuit work on a contingency basis, meaning you pay nothing out of pocket to participate. Your attorney takes a percentage of your settlement or verdict only if the case succeeds.

Standard contingency fee structure:

• 33% to 40% of your total recovery goes to the attorney
• If you receive nothing, you owe nothing
• Case expenses (filing fees, expert witnesses, medical record retrieval) are typically advanced by the law firm and deducted from your share at settlement

This fee structure exists specifically so that regular people can access the legal system without needing to write a $50,000 check to a law firm. It’s the equalizer that lets a diabetic patient go up against a $50 billion company.

Some firms charge on the lower end (33%) for cases that settle before trial. If the case goes to trial, the percentage may increase to 40%. Make sure you understand this distinction before signing a retainer agreement.

You should ask your attorney three questions before signing:

• What is your contingency percentage, and does it change if the case goes to trial?
• Are case costs deducted before or after the contingency fee is calculated?
• What happens if the case is unsuccessful?

Transparency here is important. A good attorney will answer these questions without hesitation.

Key Takeaway: Joining the Dexcom G7 lawsuit costs you nothing upfront; attorneys work on contingency and only get paid if you get paid, typically 33% to 40% of your recovery.

Dexcom CGM Defect Claims: The Bigger Picture

Dexcom CGM defect claims extend beyond the G7 to encompass a broader pattern of quality control issues across the company’s product line. The G6 recall, G7 complaints, and ongoing FDA scrutiny paint a picture of a company that may have prioritized speed to market over patient safety.

Dexcom controls roughly 30% of the global CGM market. Its primary competitors, Abbott (FreeStyle Libre) and Medtronic (Guardian), have faced their own lawsuits and recalls. But Dexcom’s position as the premium, most expensive option raises the bar for what consumers expect.

The bigger picture includes:

• Dexcom’s rapid product release cycle (G5 to G6 to G7 in roughly 5 years)
• Cost-cutting in manufacturing that may have affected sensor quality
• Customer service infrastructure that can’t keep up with replacement demands
• Stock price pressure that incentivizes shipping more sensors faster

The CGM market is projected to reach $16 billion by 2028. With that kind of money at stake, there’s enormous corporate incentive to get products out the door quickly. Plaintiffs argue this pressure led Dexcom to ship sensors that weren’t ready.

Individual defect claims add up to something larger: a systemic problem. When thousands of people report the same failures with the same device, the issue is not user error. It’s manufacturing.

The Dexcom CGM defect claims tell a story that goes beyond any single broken sensor. They reflect what happens when a medical device company grows faster than its quality systems can handle.

Frequently Asked Questions

Is there a class action lawsuit against Dexcom for the G7 in 2026?

Yes, lawsuits against Dexcom over the G7 are actively moving through federal courts in 2026.

Formal class certification has not been granted yet, but multiple plaintiff firms are pursuing consolidated litigation.

Cases continue to grow as more users report sensor failures and health-related injuries.

How much money can I get from the Dexcom G7 lawsuit?

Estimated payouts range from $500 to $100,000 or more depending on the severity of harm you experienced.

Minor sensor failure claims will pay less than claims involving hospitalization or serious medical events.

No official settlement amounts have been set yet since the case is still in litigation.

What is the deadline to file a Dexcom G7 lawsuit claim?

Deadlines vary by state, with most statutes of limitation set at 2 to 4 years from the date of injury or discovery.

If your injury occurred in 2024, some state deadlines could expire as early as 2026.

Contact an attorney soon to make sure you don’t miss your window.

Does the Dexcom lawsuit cover sensor adhesive problems?

Yes, adhesive failure and allergic reactions from Dexcom G7 adhesive chemicals are included in the lawsuit claims.

Plaintiffs allege that Dexcom used a skin-sensitizing chemical (isobornyl acrylate) without adequate warnings.

Skin irritation, blistering, and scarring are all covered complaint categories.

Do I need a lawyer to join the Dexcom G7 class action?

You should work with an attorney to protect your interests, and it costs you nothing upfront.

Lawyers handling these cases work on contingency, meaning they only get paid if you receive compensation.

Filing without legal representation is possible but puts you at a significant disadvantage against Dexcom’s corporate legal team.

What to Do Next

The Dexcom G7 class action lawsuit is real, it’s growing, and 2026 is a pivotal year for anyone thinking about filing a claim. If your G7 sensor failed, gave you bad readings, or caused a medical scare, your experience matters.

Start by collecting your evidence now. Medical records, app screenshots, purchase receipts, and any communication with Dexcom support all strengthen your case.

Reach out to a qualified product liability attorney for a free case evaluation. The clock is ticking on filing deadlines, and early claimants are often in the strongest position when settlements eventually happen.

Before you go further, consider reading What Happens at a Mediation for a Lawsuit in 2026

This may also interest you — MyChart Class Action Lawsuit: Key Facts for 2026

Along the same lines: Business Lawsuit Israel 2026: Full Filing and Payout Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.